Biotech Values

[DewDiligence]

BI presents phase-2b SVR data for BI 201335 from SILEN-C1 and SILEN-C2 studies in first- and second-line settings, respectively:

http://finance.yahoo.com/news/Positive-Phase-2-Results-prnews-922897516.html?x=0&.v=1

I’m somewhat surprised that BI—a private company that does not have to cater to Wall Street—is taking BI 201335 into phase-3 as an addend to SoC (#msg-61666265) rather than focusing entirely on all-oral combos. This may be telling us that BI doesn’t think much of its non-nuke, BI 207127, with which BI 201335 has been paired (#msg-56271789). Nevertheless, there are other oral agents out there that BI 201335 could conceivably be combined with.